BRPI0906810A2 - anticorpo contra pcrv - Google Patents

anticorpo contra pcrv

Info

Publication number
BRPI0906810A2
BRPI0906810A2 BRPI0906810A BRPI0906810A BRPI0906810A2 BR PI0906810 A2 BRPI0906810 A2 BR PI0906810A2 BR PI0906810 A BRPI0906810 A BR PI0906810A BR PI0906810 A BRPI0906810 A BR PI0906810A BR PI0906810 A2 BRPI0906810 A2 BR PI0906810A2
Authority
BR
Brazil
Prior art keywords
pcrv
monoclonal antibody
present
pharmaceutical composition
pseudomonas aeruginosa
Prior art date
Application number
BRPI0906810A
Other languages
English (en)
Inventor
Sato Takafumi
Tsuji Toshinaga
Yamano Yoshinori
Numata Yoshito
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of BRPI0906810A2 publication Critical patent/BRPI0906810A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"anticorpos monoclonais contra pcrv ou parte dos mesmos, sua composição farmacêutica, hibridoma e uso dos referidos anticorpos". a presente invenção refere-se a um meio eficaz para terapia de infecção, particularmente infecção com pseudomonas aeruginosa. refere-se a um anticorpo monoclonal contra pcrv, ou uma parte do mesmo, e uma composição farmacêutica contendo o mesmo como um ingrediente ativo. concretamente, o anticorpo monoclonal da presente invenção tem excelente atividade de inibição sobre citotoxicidade com relação a uma célula-alvo de pseudomonas aeruginosa. também, o anticorpo monoclonal da presente invenção tem alta afinidade com pcrv.
BRPI0906810A 2008-01-10 2009-01-08 anticorpo contra pcrv BRPI0906810A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008003214 2008-01-10
PCT/JP2009/050118 WO2009088032A1 (ja) 2008-01-10 2009-01-08 ＰｃｒＶに対する抗体

Publications (1)

Publication Number Publication Date
BRPI0906810A2 true BRPI0906810A2 (pt) 2019-10-01

Family

ID=40853144

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906810A BRPI0906810A2 (pt) 2008-01-10 2009-01-08 anticorpo contra pcrv

Country Status (13)

Country Link
US (1) US8501179B2 (pt)
EP (2) EP2248826B1 (pt)
JP (1) JP4766716B2 (pt)
KR (1) KR101259239B1 (pt)
CN (1) CN102137870B (pt)
AU (1) AU2009203426C1 (pt)
BR (1) BRPI0906810A2 (pt)
CA (1) CA2711863C (pt)
EA (1) EA020544B1 (pt)
ES (1) ES2426093T3 (pt)
PL (1) PL2248826T3 (pt)
PT (1) PT2248826E (pt)
WO (1) WO2009088032A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA020544B1 (ru) 2008-01-10 2014-12-30 Шионоги Энд Ко., Лтд. АНТИТЕЛА ПРОТИВ PcrV
SG174225A1 (en) * 2009-03-11 2011-10-28 Shionogi & Co Humanized pcrv antibody having anti-pseudomonal activity
RU2014100111A (ru) 2011-06-10 2015-07-20 МЕДИММЬЮН, ЭлЭлСи МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
HRP20201370T1 (hr) 2011-11-07 2020-11-27 Medimmune Limited Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule
EP2820043B1 (en) 2012-03-02 2020-01-15 Ablynx N.V. Biparatopic pseudomonas aeruginosa pcrv binding single variable domain antibodies
GB201518668D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
EP3983015A1 (en) 2019-06-11 2022-04-20 Regeneron Pharmaceuticals, Inc. Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
CN118620074A (zh) * 2020-06-01 2024-09-10 北京三诺佳邑生物技术有限责任公司 特异性识别假单胞菌pcrv的抗体及其用途
AU2024307442A1 (en) 2023-06-28 2026-02-19 Universität Zu Köln Neutralizing human monoclonal antibodies against p. aeruginosa
CN118440191B (zh) * 2024-05-11 2025-06-10 重庆原伦生物科技有限公司 一种抗铜绿假单胞菌PcrV抗体的制备及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US6214973B1 (en) 1993-11-19 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human medulloblastoma cells
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
EP1666058B1 (en) * 1998-11-25 2011-12-28 MCW Research Foundation, Incorporated Method of diagnosing a Pseudomonas aeruginosa infection
US20030228324A1 (en) * 1999-05-06 2003-12-11 Malcolm Andrew J. Peptide compositions and methods of producing and using same
WO2002064161A2 (en) * 2001-01-26 2002-08-22 Mcw Research Foundation, Inc. Method and compositions for immunization with the pseudomonas v antigen
EP1761561B1 (en) 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
CN101454446A (zh) 2006-03-30 2009-06-10 明治制果株式会社 绿脓杆菌的外膜蛋白pa0427
CN101002947B (zh) * 2007-01-16 2010-08-25 湖南农业大学 一种用于细菌病治疗的靶向药物及其制备方法
WO2009005040A1 (ja) * 2007-06-29 2009-01-08 Meiji Seika Kaisha Ltd. 緑膿菌の外膜タンパク質pa4710
BRPI0819598A2 (pt) 2007-11-30 2017-05-09 Kalobios Pharmaceuticals Inc anticorpos para o antígeno pcrv da pseudomonas aeruginosa
EA020544B1 (ru) 2008-01-10 2014-12-30 Шионоги Энд Ко., Лтд. АНТИТЕЛА ПРОТИВ PcrV
SG174225A1 (en) * 2009-03-11 2011-10-28 Shionogi & Co Humanized pcrv antibody having anti-pseudomonal activity

Also Published As

Publication number Publication date
WO2009088032A1 (ja) 2009-07-16
US20110150896A1 (en) 2011-06-23
EP2248826A4 (en) 2011-03-02
EA020544B1 (ru) 2014-12-30
CA2711863C (en) 2014-06-10
EP2248826B1 (en) 2013-06-12
CN102137870A (zh) 2011-07-27
JP4766716B2 (ja) 2011-09-07
PL2248826T3 (pl) 2013-11-29
US8501179B2 (en) 2013-08-06
ES2426093T3 (es) 2013-10-21
EA201070826A1 (ru) 2011-04-29
PT2248826E (pt) 2013-09-06
CA2711863A1 (en) 2009-07-16
KR101259239B1 (ko) 2013-04-29
EP2599792A1 (en) 2013-06-05
AU2009203426A1 (en) 2009-07-16
AU2009203426B2 (en) 2011-11-24
JPWO2009088032A1 (ja) 2011-05-26
KR20100103675A (ko) 2010-09-27
CN102137870B (zh) 2014-09-03
EP2248826A1 (en) 2010-11-10
AU2009203426C1 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
BRPI0906810A2 (pt) anticorpo contra pcrv
BRPI0821110B8 (pt) anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
MX2011009100A (es) Anticuerpo humanizado pcrv que tiene actividad anti-pseudomonal.
BRPI0519424B8 (pt) compostos, composição e uso dos ditos compostos para a preparação de um medicamento para prevenção ou tratamento de um distúrbio de proliferação celular ou infecção microbiana
BRPI0811262A2 (pt) Composto, composto ou sal do mesmo, composição farmacêutica, modulador de receptor de glicocorticóide, método para prevenção e/ou tratamento de bistúrbios metabólicos, doenças inflamatórias, doenças auto-imunes, doenças alérgicas, doenças do sistema nervoso central, doenças cardiovasculares, doenças relacionadas com homeostase ou glaucoma, e uso de pelo menos um composto ou um sal do mesmo
BR112012014984A2 (pt) anticorpos dirigidos contra o receptor da transferrina e as suas utilizacoes para a imunoterapia dos tumores que dependem do ferro
BRPI0807487A8 (pt) Uso de antagonistas de il-23 para o tratamento de infecção
BR112012019098A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer e anticorpo
BRPI0608690B8 (pt) uso de uma composição antimicrobiana
BR112015023391A2 (pt) formulações compreendendo conjugado droga-anticorpo anti-egfr
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
WO2021021837A3 (en) Anti-pvrig antibodies formulations and uses thereof
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
BR112013008140A2 (pt) "compostos imidazotriazinona".
BRPI0922435A2 (pt) "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
WO2007138116A3 (de) Pharmazeutische zusammensetzung zur behandlung von virusinfektionen und/oder tumorerkrankungen durch inhibition der proteinfaltung und des proteinabbaus
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
WO2010080580A3 (en) Extended-release pharmaceutical formulations
CR10032A (es) Preparación sólida
CA2821268C (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
EP2816034A3 (en) Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction
BRPI0909296A2 (pt) uso de pelo menos um princípio ativo, e, composições cosmética, farmacêutica e/ou dermatológica
BR112021023927A2 (pt) Composto, e, composição farmacêutica
WO2018094300A8 (en) ANTI-GITR ANTIGEN BINDING PROTEINS AND METHODS OF USE

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2544 DE 08-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]